2 results
Approved WMOPending
To demonstrate in a phase III study that the addition of the monoclonal anti-T cell antibody alemtuzumab added to standard CHOP chemotherapy followed by autologous stam cell transplantation will increase the response, event-free survival,…
Approved WMORecruiting
The current study has been designed to demonstrate that MOCA using Flebogrif is not inferior to EVLA for the treatment of GSV insufficiency.